Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.39 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.30 |
| ▸ | RAPGEF4 | Q8WZA2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8327334 | 0.97 | HTR1D (0.40) | HTR1DHTR1BRAPGEF4ALDH1A1TAS1R3 | |
| SCHEMBL22453893 | 0.84 | CYP3A4 (0.37) | HTR1DHTR1BRAPGEF4ALDH1A1TAS1R3 | |
| Hydrochloric Acid SCHEMBL2071013 | 0.79 | RAPGEF4 (0.57) | RAPGEF4ALDH1A1LMNA | |
| SCHEMBL18960495 | 0.79 | GABRA1 (0.45) | HTR1DHTR1BRAPGEF4ALDH1A1TAS1R3 | |
| SCHEMBL3212255 | 0.76 | RAPGEF4 (0.60) | RAPGEF4ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL28019737 | 0.75 | RAPGEF4 (0.43) | RAPGEF4LMNA | |
| SCHEMBL1285327 | 0.75 | CYP3A4 (0.37) | HTR1DHTR1BRAPGEF4ALDH1A1TAS1R3 | |
| Hydrochloric Acid SCHEMBL20984266 | 0.74 | CYP3A4 (0.39) | MAPTCYP3A4TSHR | |
| SCHEMBL29021130 | 0.74 | HTR1D (0.41) | HTR1DHTR1BRAPGEF4ALDH1A1TAS1R3 | |
| Hydrochloric Acid SCHEMBL26097882 | 0.73 | POLB (0.56) | HTR1DHTR1BRAPGEF4ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119790055-A | Pyrazolopyrimidine compound and medical use thereof | 日本烟草产业株式会社 | 2025-04-08 | — | — | CN | disclosed |
| CN-117881682-A | 6-amino pyrazolopyrimidine compound and medical application thereof | 日本烟草产业株式会社 | 2024-04-12 | — | — | CN | disclosed |
| CN-107759522-B | Carboxylic acid derivative, preparation method thereof and application thereof in medicine | 浙江海正药业股份有限公司 | 2023-04-14 | — | — | CN | disclosed |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-9452999-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2016-09-27 | — | — | US | disclosed |
| EP-2673260-B1 | GLUCAGON RECEPTOR MODULATOR | PFIZER (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20150266859-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-9073871-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140371467-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140306203-A1 | METAL COMPLEX AND LIGHT-EMITTING DEVICE COMPRISING THE METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-10-16 | — | — | US | disclosed |
| US-8859591-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2673260-A1 | GLUCAGON RECEPTOR MODULATOR | Pfizer Inc (US) | 2013-12-18 | — | — | EP | disclosed |
| US-20130296355-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER (US) | 2013-11-07 | — | — | US | disclosed |
| US-8507533-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2013-08-13 | — | — | US | disclosed |
| WO-2012107850-A1 | GLUCAGON RECEPTOR MODULATOR | PFIZER INC. (US) | 2012-08-16 | — | — | WO | disclosed |
| US-20120202834-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-5968944-A | TREATING STRESS AND ANXIETY RELATED DISORDERS | PFIZER INC. (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0764153-A1 | SUBSTITUTED PYRAZOLES HAVING CORTICOTROPIN-RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY | PFIZER INC. (US) | 1997-03-26 | — | — | EP | disclosed |
| WO-1995033727-A1 | SUBSTITUTED PYRAZOLES HAVING CORTICOTROPIN-RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY | PFIZER INC. (US) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266859-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | HTR1D 782/4885HTR1B 296/4885SIGMAR1 1333/4885 |
| US-20130296355-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | HTR1D 782/4885HTR1B 296/4885SIGMAR1 1333/4885 |
| US-20140371467-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | HTR1D 782/4885HTR1B 296/4885SIGMAR1 1333/4885 |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | HTR1D 782/4885HTR1B 296/4885SIGMAR1 1333/4885 |
| US-20120202834-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | HTR1D 782/4885HTR1B 296/4885SIGMAR1 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.